Canopy Growth's Balancing Act: Sharper Numbers, a Restatement, and a Sector Tailwind

Canopy Growth posts best operational numbers in years with 13% revenue growth, but restated financials and auditor resignation cloud investor sentiment.

Canopy Growth has spent years as the cannabis industry's most visible cautionary tale — a company whose once-dizzying growth narrative gave way to serial disappointments, restructuring efforts, and, most recently, a fresh accounting headache. Yet the latest chapter is more complicated than simple decline. The company is simultaneously posting its best operational numbers in years and wrestling with a credibility problem of its own making.

The quarterly figures, released August 7, tell the encouraging side of the story. Consolidated net revenue for the first quarter of fiscal 2027 rose 13 percent to 81.2 million Canadian dollars, while the net loss contracted by 68 percent to 14.6 million Canadian dollars. Adjusted gross margin expanded to 31 percent from 25 percent a year earlier, and the adjusted EBITDA loss narrowed 59 percent to 3.2 million Canadian dollars. By any measure, this is a company that appears to be getting a grip on its cost structure.

But the same week brought a sobering counterweight. Canopy Growth disclosed that its audited financial statements for fiscal 2024 and 2025 can no longer be relied upon, owing to a non-cash classification error involving share-settled warrants. The company's auditor, PKF O'Connor Davies, resigned, with MNP LLP stepping in for the fiscal year ending March 31, 2027. For a business that has spent years trying to rebuild investor trust, the timing could hardly be worse.

Investors, however, have found reason to look past the accounting noise — at least for now. The stock has been carried higher by a broad sector rally across North American markets. Tilray advanced roughly six percent and Aurora Cannabis climbed four percent in a move that analysts attribute to a return of institutional interest in established operators. Canopy Growth has ridden that wave, lifting itself 18 percent off its 52-week low.

The technical picture is nonetheless mixed. The shares are testing their 100-day moving average at 0.8854 euros, and a sustained breakout above that level would confirm a short-term uptrend. The relative strength index sits at a neutral 57, while annual volatility of 47 percent underscores the sector's inherent unpredictability. At Thursday's close of 0.8850 euros, the stock was up 0.5 percent on the day and 11 percent over the past month — though still down 15 percent since the start of the year.

That persistent weakness reflects a market that remains deeply skeptical. The shares trade 56 percent below their December peak of 2.00 euros, a gap that speaks to how little credit the market has been willing to extend for operational improvements. Analysts have responded to the quarterly results by trimming their consensus target by 13 percent to 2.02 Canadian dollars from 2.33 Canadian dollars, based on the views of seven analysts.

Management, for its part, is pressing forward on multiple fronts. A virtual shareholder meeting is scheduled for September 25, with a proposed share consolidation ranging from 1-for-5 to 1-for-15 on the agenda — a familiar tool for depressed stocks that also signals just how far the share price has fallen. Constellation Brands, the company's onetime strategic backer, held approximately 5.8 percent of the company on a converted basis as of July 31, a reduced but still meaningful stake.

The international business is emerging as a key growth lever. The EU-GMP certification for the Kincardine facility in Canada was renewed on August 14, preserving the company's ability to export medical cannabis to Europe. At the Canaccord Genuity Growth conference on August 11, management outlined fiscal 2027 targets of positive adjusted EBITDA and European revenue run-rate of 100 to 150 million Canadian dollars. The launch of "Deelish," a budget brand of high-potency flower and pre-rolls, signals a push for share in the Canadian market.

The sector-wide revival has shifted the conversation somewhat, with attention turning to whether Canopy Growth's cost discipline and portfolio pruning can finally translate into sustained credibility. The company's U.S. arm, Canopy USA, remains the pivotal variable — aligning production with actual consumer demand will determine whether the consolidated strategy holds up in an increasingly competitive environment.

The market's verdict is still out. Operational progress is real, but so is the accounting overhang. Canopy Growth may be writing a more disciplined chapter, but it will take several quarters of dependable results before the market fully rewrites its opinion.